Nautilus Biotechnology, INC Form 4 insider transactions

Kentaro Suzuki, Chief Marketing Officer of Nautilus Biotechnology, receives stock options for 375,000 shares.

Matthew S. McIlwain, a director at Nautilus Biotechnology, acquired 45,000 stock options on June 14, 2024, according to a recent SEC filing.

Director Michael Seth Altman reports acquisition of 45,000 stock options in Nautilus Biotechnology, Inc.

Perceptive Advisors LLC, Perceptive Life Sciences Master Fund Ltd., and Joseph Edelman report changes in beneficial ownership of Nautilus Biotechnology, Inc. stock due to option grants.

Director Karen Akinsanya of Nautilus Biotechnology acquired 45,000 stock options on June 14, 2024, according to a recent SEC Form 4 filing.

Melissa B. Epperly, a director at Nautilus Biotechnology, acquired 45,000 stock options on June 14, 2024, according to a Form 4 filing with the SEC.

Director Vijay Satyanand Pande acquired 45,000 stock options in Nautilus Biotechnology, Inc. on June 14, 2024.

Director Farzad Nazem of Nautilus Biotechnology acquired 45,000 stock options on June 14, 2024, according to a Form 4 filing with the SEC.

Director Matthew L. Posard reports the acquisition of stock options in Nautilus Biotechnology, Inc.

Nautilus Biotechnology's CEO, Sujal M. Patel, recently acquired additional shares of common stock, increasing his beneficial ownership.

Nautilus Biotechnology CEO Sujal M. Patel has been actively purchasing company stock, increasing his direct and indirect holdings.

Nautilus Biotechnology CEO Sujal M. Patel reports the acquisition of 650,000 stock options in the company.

Parag Mallick, Chief Scientist at Nautilus Biotechnology, acquired 280,000 stock options on March 1, 2024, according to a recent SEC filing.

Nicholas A. Nelson, CBO & Senior VP of Business Development at Nautilus Biotechnology, acquired 160,000 stock options on March 1, 2024.

Anna Mowry, CFO and Treasurer of Nautilus Biotechnology, received stock options for 160,000 shares on March 1, 2024.

Gwen E. Weld, Chief People Officer of Nautilus Biotechnology, reports the acquisition of stock options.

Matthew B. Murphy, General Counsel of Nautilus Biotechnology, acquired 160,000 stock options on March 1, 2024, according to a Form 4 filing with the SEC.

Subramanian Sankar, Senior VP of Product Development at Nautilus Biotechnology, acquired stock options for 160,000 shares on March 1, 2024.

Mary E. Godwin, Senior VP of Operations at Nautilus Biotechnology, acquired 160,000 stock options on March 1, 2024, according to a recent SEC filing.